Stories
PharmEasy Parent Clears Debt and Eyes Strategic IPO After Profitability
M
Moneycontrol•05-10-2026, 16:19
PharmEasy Parent Clears Debt and Eyes Strategic IPO After Profitability
- •API Holdings, the parent company of PharmEasy, has successfully repaid its outstanding term debt of Rs 1,050 crore using proceeds from a partial stake sale in Thyrocare and internal accruals.
- •Managing Director and CEO Rahul Guha stated that the company is targeting profitability for its business excluding Thyrocare by March 2027 before deciding on an initial public offering or a merger.
- •All operating businesses including PharmEasy, Ascent and Aknamed are already EBITDA positive before central cost allocations, with financial backing from global investors like TPG and Temasek.
- •PharmEasy is transforming from a traditional online medicine delivery platform into an integrated outpatient healthcare service, with higher-margin products contributing around 25 percent of revenue.
Key Questions Answered
API Holdings cleared its outstanding term debt of Rs 1,050 crore using proceeds from a partial stake sale in Thyrocare along with internal accruals, while keeping a 51.02 percent controlling stake in the diagnostics company.
Managing Director and CEO Rahul Guha stated that API Holdings is targeting profitability in its business excluding Thyrocare by March 2027. At the consolidated level, including Thyrocare, the company has already turned profitable.
PharmEasy is transitioning into an integrated outpatient healthcare platform that combines pharmacy services with diagnostics, doctor consultations, and other outpatient offerings. Higher-margin products and services already contribute about 25 percent of its revenue.
